Emerald Advisers LLC Sells 300,738 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Emerald Advisers LLC decreased its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 77.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 89,098 shares of the medical device company's stock after selling 300,738 shares during the quarter. Emerald Advisers LLC owned approximately 0.18% of AtriCure worth $2,723,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ATRC. LPL Financial LLC raised its stake in AtriCure by 5.4% during the 4th quarter. LPL Financial LLC now owns 11,465 shares of the medical device company's stock valued at $350,000 after purchasing an additional 584 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of AtriCure during the fourth quarter valued at approximately $321,000. Sei Investments Co. lifted its holdings in shares of AtriCure by 6.1% in the fourth quarter. Sei Investments Co. now owns 107,290 shares of the medical device company's stock worth $3,279,000 after buying an additional 6,152 shares in the last quarter. American Century Companies Inc. bought a new position in shares of AtriCure during the fourth quarter worth $516,000. Finally, Intech Investment Management LLC grew its stake in AtriCure by 41.4% during the fourth quarter. Intech Investment Management LLC now owns 21,520 shares of the medical device company's stock valued at $658,000 after acquiring an additional 6,306 shares in the last quarter. Institutional investors own 99.11% of the company's stock.

AtriCure Trading Down 7.4 %

Shares of AtriCure stock traded down $2.54 during trading on Friday, hitting $31.83. The stock had a trading volume of 538,818 shares, compared to its average volume of 675,293. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.11. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The firm's fifty day simple moving average is $37.97 and its 200-day simple moving average is $33.93. The stock has a market cap of $1.56 billion, a PE ratio of -33.50 and a beta of 1.53.

Remove Ads

Analysts Set New Price Targets

Several analysts have commented on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $51.00 price target on shares of AtriCure in a research note on Thursday. BTIG Research reiterated a "buy" rating on shares of AtriCure in a research report on Thursday. JPMorgan Chase & Co. dropped their price target on AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday. Oppenheimer upped their price objective on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. Finally, Stifel Nicolaus raised their target price on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $49.44.

Insiders Place Their Bets

In other AtriCure news, Director Karen Prange sold 6,100 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now owns 17,828 shares in the company, valued at $679,603.36. This trade represents a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.20% of the stock is owned by insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.